Navigation Links
NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011

LAWRENCE, Mass., Nov. 3, 2011 /PRNewswire/ --


- Revenue Increases to $55.9 million, up 24% from Q3'10

- Home Market Increases to $27.2 million, up 22% from Q3'10

- Gross Margin Increases to 35%, up from 33% in Q3'10

NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported record financial results for the third quarter ended September 30, 2011, with total revenue well above the top end of its guidance range.


Revenue for the third quarter of 2011 increased to $55.9 million, an increase of 24 percent when compared with revenue of $45.0 million for the third quarter of 2010.  The growth was driven by strong operating performance across the Company's business.

The Company grew Home revenue to $27.2 million for the third quarter of 2011, representing an increase of 22 percent when compared with revenue of $22.3 million for the third quarter of 2010.  Critical Care revenue grew to $9.2 million for the third quarter of 2011, representing an increase of 35 percent when compared with revenue of $6.8 million for the third quarter of 2010.  Revenue for In-Center, from the Company's Medisystems business, increased to $19.5 million for the third quarter of 2011, representing an increase of 23 percent when compared with revenue of $15.9 million for the third quarter of 2010.  

"Not only was this a record quarter with respect to revenues, but also one where we made meaningful progress in advancing metrics across our business," stated Jeffrey H. Burbank, CEO of NxStage Medical, Inc.  "These results are strong validation of our business model and we see significant opportunities across our business to advance our long term growth strategy.  We are particularly pleased with the growing strength of clinical data showing that patients benefit from more frequent hemodialysis and that they live longer and healthier lives."

NxStage reported a net loss of $5.3 million, or ($0.10) per share, for the third quarter of 2011 compared with a net loss of $8.2 million, or ($0.17) per share, for the third quarter of 2010.

For the third quarter of 2011, the Company reported Adjusted EBITDA, adjusted for stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses of $2.4 million, compared with an Adjusted EBITDA of $0.5 million in the third quarter of 2010.  (See the exhibits for a reconciliation of this non-GAAP measure.)


For the fourth quarter of 2011, the Company is forecasting revenue to be within a range of $55.5 to $56.5 million.  At this revenue level, the Company would expect a net loss in the range of $4.5 to $5.5 million or ($0.08) to ($0.10) per share, and Adjusted EBITDA in the range of $1.5 to $2.5 million for the fourth quarter of 2011.  

The Company's fourth quarter revenue guidance translates to an upward revision of the Company's annual guidance, putting expected revenue above the top end of its previous range. The Company now expects annual revenue to be within a range of $216 to $217 million compared with previous guidance for revenue to be within a range of $210 to $215 million.  The Company continues to expect a net loss in the range of $19 to $23 million or ($0.36) to ($0.43) per share, and for Adjusted EBITDA to be in the range of $6.0 million to $10.0 million for the 2011 fiscal year.   The Company expects the fourth quarter gross margin percentage to be between 37 and 38 percent.

This release contains a non-GAAP financial measure.  A reconciliation of the Company's non-GAAP financial measure to its most comparable GAAP financial measure is in the exhibits to this press release.

Conference Call:NxStage will also host a conference call today at 9:00 a.m. Eastern Time to discuss its third quarter financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international).  The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at

A replay of the conference call will be available 2 hours after the conclusion of the call through November 17, 2011.  To access the replay dial 855-859-2056 (domestic) or 404-537-3406 (international).  The conference ID is 17404745. An online archive of the conference call can be accessed via the investor relations section of the Company's website at

About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin and Adjusted EBITDA numbers, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Inc., Fresenius, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the period ended June 30, 2011.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.Contact:Kristen K. Sheppard, Esq.VP, Investor Relationsksheppard@nxstage.comNon-GAAP Financial Measure

The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA adjusted for stock based-compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses) to understand operational cash usage.  The Company believes the non-GAAP financial measure provides useful and supplementary information allowing investors greater transparency to one measure used by management.  The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial measures.  The non-GAAP financial measure is reconciled to the most comparable GAAP financial measure below.

NxStage Medical, Inc.Condensed Consolidated Statements of Operations(in thousands, except per share data)(unaudited)Three Months EndedNine Months EndedSeptember 30,September 30,2011201020112010Revenues

$55,903$45,033$160,235$129,449Cost of revenues

36,36330,073103,79788,914Gross profit

19,54014,96056,43840,535Operating expenses:Selling and marketing

9,4468,45228,02525,034Research and development


4,7093,78813,29810,831General and administrative

5,7086,02316,75016,604Total operating expenses

23,25121,39568,76761,838Loss from operations

(3,711)(6,435)(12,329)(21,303)Other expense:Interest expense

(1,186)(1,176)(3,513)(3,432)Other (expense), net

(146)(341)(342)(128)(1,332)(1,517)(3,855)(3,560)Net loss before income taxes

(5,043)(7,952)(16,184)(24,863)Provision for income taxes

235212654556Net loss

$ (5,278)$ (8,164)$ (16,838)$ (25,419)Net loss per share, basic and diluted

$   (0.10)$   (0.17)$
(0.54)Weighted-average shares outstanding, basic and diluted

54,42848,04953,95347,501NxStage Medical, Inc.Condensed Consolidated Balance Sheets(in thousands, except share data)(unaudited)September 30,December 31,20112010ASSETSCurrent assets:Cash and cash equivalents$
4,339Accounts receivable, net17,49714,107Inventory35,56334,950Prepaid expenses and other current assets3,1042,084Total current assets157,411155,480Property and equipment, net14,2768,290Field equipment, net12,71813,660Deferred cost of revenues41,35540,081Intangible assets, net23,31425,412Goodwill42,69842,698Other assets1,497473Total assets$
286,094LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable$
,811Accrued expenses16,26519,537Current portion of long-term debt-43Total current liabilities35,46036,391Deferred revenues56,68255,366Long-term debt42,52140,454Other long-term liabilities6,9941,754Total liabilities141,657133,965Commitments and contingenciesStockholders’ equity:Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2011 and December 31, 2010--Common stock: par value $0.001, 100,000,000 shares authorized; 55,617,552  and 54,043,317 shares issued as of September 30, 2011 and December 31, 2010, respectively5553Additional paid-in capital485,191465,642Accumulated deficit(325,264)(308,426)Accumulated other comprehensive income14685Treasury stock, at cost: 480,923 and 325,104 shares as of September 30, 2011 and December 31, 2010, respectively(8,516)(5,225)Total stockholders’ equity151,612152,129Total liabilities and stockholders’ equity$
286,094NxStage Medical, Inc.Cash Flows from Operating Activities(in thousands)(unaudited)Nine Months EndedSeptember 30,20112010Cash flows from operating activities:Net loss

$ (16,838)$ (25,419)Adjustments to reconcile net loss to netcash used in operating activities:Depreciation and amortization

17,41516,879Stock-based compensation


2,3871,750Changes in operating assets and liabilities:Accounts receivable


(15,196)(20,504)Prepaid expenses and other assets

(2,067)(327)Accounts payable

2,296(3,376)Accrued expenses and other liabilities

1953,980Deferred revenues

1,31614,087Net cash used in operating activities

$   (3,740)$   (2,248)NxStage Medical, Inc.Revenues by Segment(in thousands)Three Months EndedNine Months EndedSeptember 30,September 30,2011201020112010System One segment  Home

$ 27,218$ 22,346$   80,276$   62,204  Critical Care

9,1706,81725,19919,528Total System One segment

36,38829,163105,47581,732In-Center segment


$ 55,903$ 45,033$ 160,235$ 129,449NxStage Medical, Inc.Non-GAAP Financial Measures(in millions)(unaudited)Three Months EndedNine Months EndedSeptember 30,September 30,2011201020112010Net loss

$ (5.3)$ (8.2)$ (16.8)$ (25.4)Less: Depreciation, amortization, interest, and taxes

7.57.621.921.0Less: Adjusting items* EBITDA gain (loss)

$  2.4$  0.5$
5.3$   (1.0)* Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expensesNxStage Medical, Inc.Non-GAAP Financial Guidance(amounts in millions)Three Months EndedDecember 31, 2011High

EstimateNet loss

(5.5)Less: Depreciation, amortization, interest, and taxes

7.37.3Less: Adjusting items*

(0.3)(0.3)Adjusted EBITDA gain

.5* Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage® Ranked Number 141 on the Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
2. NxStage® to Report Third Quarter Fiscal 2011 Financial Results
3. NxStage Says Thank You to Patients and Care Partners at the 2nd Annual NxStageUsers Meet-Up and Conference in New Orleans
4. NxStage System One Patients Join Patient Advocacy Groups on Capitol Hill
5. NxStage Board Member Dr. Barry M. Straube Honored with Prestigious Award from the American Association of Kidney Patients
6. NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis
7. NxStage to Present at UBS Global Life Sciences Conference
8. NxStage Medical Founder and CEO Jeffrey Burbank Honored With Mass High Tech All-Star Award
9. Former NxStage System One User Celebrates One-Year Kidney Transplant Anniversary
10. NxStage® Highlights Non-Medical Emergency Preparedness Guidebook for System One™ Home Hemodialysis Patients
11. NxStage Celebrates Seven Year Anniversary of IU Healths Home Hemodialysis Program and Patient Milestones
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that clinical ... will be presented at the 2015 American College ... include measures of sustained response in IBS-C patients ... randomized Phase 2 trial. The meeting will be ...
(Date:10/8/2015)... DIEGO , Oct. 8, 2015  Trovagene, ... molecular diagnostics, today announced the presentation of results ... of its Precision Cancer Monitoring SM (PCM) ... be critical for physicians to determine appropriate therapy ... scientific officer of Trovagene is delivering the results ...
(Date:10/8/2015)... , Oct. 8, 2015  Following months of investigation, ... in the nation alleging that the anticoagulant Xarelto,s recommended dosage ... results. Philadelphia on behalf of ... ischemic stroke because the drug didn,t work as the manufacturer ... numerous other suits shortly on behalf of clients from across ...
Breaking Medicine Technology:
... Md., April 18, 2011 Sigma-Tau Pharmaceuticals, Inc. ... approval from the U.S. Food and Drug Administration ... the oncology medicine ONCASPAR® (pegaspargase).  ONCASPAR is the ... a key component in the treatment of acute ...
... April 18, 2011 Quest Diagnostics Incorporated (NYSE: ... testing, information and services, today announced the availability of ... of patient response to peginterferon alpha-based therapy for hepatitis ... the test to physicians and other healthcare providers in ...
Cached Medicine Technology:
(Date:10/9/2015)... ... ... A new health tool that helps identify if a sore throat is serious, ... just in time for the cold and flu season, which the Center for Disease ... U.S., the real start of cold/flu season is the start of the school year, ...
(Date:10/9/2015)... ... October 09, 2015 , ... Smoke alarms can save lives. In fact, ... risk of dying in reported home fires in half. As part of Fire Prevention ... are property installed and maintained. , Half of home fire deaths result from fires ...
(Date:10/9/2015)... Huntington Beach, CA (PRWEB) , ... October 09, ... ... Rassouli, is now offering a special promotion on Invisalign, the orthodontic system that ... many reasons. The aligners are almost invisible against the teeth, which allow patients ...
(Date:10/9/2015)... ... October 09, 2015 , ... Matrix IT ... product specifications for TRACTUS, the world’s first sterile field scanner. , ... response to the FDA’s recent Unique Device Identifier (UDI) Final Rule, which will ...
(Date:10/9/2015)... Washington, DC (PRWEB) , ... October 09, 2015 , ... ... agreement from the US Centers for Disease Control and Prevention (CDC) to improve the ... 14 years that AAFA has been awarded a project by the CDC and allows ...
Breaking Medicine News(10 mins):
... Network of America, LLC (DNoA) announced today the completion ... Blue Cross Blue Shield of Michigan (BCBSM), a nonprofit ... in Michigan, in addition to members of Michigan-headquartered groups ... , The acquisition brings two strategically focused companies -- ...
... BCBSM Customers Expanded National Dental Network; Solidify BCBSM Position as ... July 1 Blue Cross Blue Shield of Michigan announced ... acquired by Dental Network of America, LLC (DNoA), a strategic ... and DNoA -- will provide BCBSM with a more competitive ...
... , WASHINGTON, July 1 Today,s 65 year old Medicare ... or ,donut hole, is eliminated, says a new analysis of ... Avalere Health. The firm also concludes that although fewer ... by 2020 some of the sickest Medicare beneficiaries will spend ...
... 1 At a bargaining session yesterday with SEIU ... at Kaiser Permanente facilities in California and the rest ... ended when the contractor refused to restore the affordable ... the year. Bargaining broke down Tuesday evening as ...
... the 2009 pistachio harvest little more than two months away, ... with production expected to exceed 2008 levels. Growing conditions have ... of nutrient-rich pistachios to meet increasing demand. , ... September and is estimated at more than 425 million pounds ...
... , WESTCHESTER, Ill., July 1 The Pediatric Brain Tumor ... Fund) and BrainLAB teamed up again this year for the ... in New York City. The June 6 event raised funds ... childhood brain tumors. , , (Photo: ...
Cached Medicine News:
... Tri-Flo® suction catheter design was created ... patients while still providing high suctioning ... (5/6, 8 or 10 Fr) feature ... catheter placement. Our complete catheter line ...
Tracheal Suction Latex Rubber Catheters - Funnel End...
Rubber bronchial coude catheter, X-ray opaque, one eye, whistle tip....
KCIs KinAir IV combines Advanced Pressure Relief Therapy with a manual wound care turn to provide optimum skin care and patient,positioning....
Medicine Products: